Group items tagged

The global market for biochips is expected to reach USD 9.1 billion in 2015 with a CAGR of 20.9% in 2009-2015, the CAGR mass is mainly supported by the Asia-Pacific, followed by the European Union. Among the major industry segments, biochips instruments are expected to exercise the highest support for the industry with a CAGR of 22.6% worldwide.

The South america industry for biomaterials is calculated to arrive at $1.7 million in 2015 from $550.2 thousand in 2008 with a CAGR of 19.5% from 2010 to 2015. In 2009, the heated biomaterial industry recorded revenues of $236.5 thousand or 37.5% of the complete biomaterial items industry.

The report entitled "Chain Reaction (PCR) in the medical application - a summary report, 2009-2015" examines the latest market trends astute PCR with an attempt to reveal the growth prospects for the near future a in-depth analysis.

The report, "the polymerase chain reaction (PCR), medical applications - Analysis Report 2009-2015", examines the recent market developments in the PCR percipient tries to reveal short-term growth prospects.

The report 'Polymerase Chain Reaction (PCR) - An Analytical Report, 2009-2015' reviews the latest PCR market trends with a perceptive attempt to disclose the near-future growth prospects.

The Brazil market for biomaterials is expected to reach $1.7 billion in 2015 from $550.2 million in 2008 with a CAGR of 19.5% from 2010 to 2015. In 2009, the orthopedic biomaterial market recorded revenues of $236.5 million or 37.5% of the total biomaterial products market.

The Brazilian market for biomaterials is expected to reach $ 1.7 billion in 2015 from 550.2 million in 2008 with a CAGR of 19.5% from 2010 to 2015. In 2009 recorded sales of orthopedic biomaterial market of $ 236.5 million or 37.5% of the total biomaterial products on the market.

With a CAGR of 7.9%, international industry value for biorepositories industry is estimated to be worth US$23.9 million by 2015.

With a CAGR of 7.9%, international industry value for biorepositories industry is estimated to be worth US$23.9 million by 2015. On a international scale, North America records for more than 30% of industry place

With a CAGR of 7.9%, the global market for tissue banks market should be useful to U.S. $ 23.9 billion in 2015. Overall, North America accounted for over 30% market share.

With a CAGR of 7.9%, the global market for tissue banks market should be useful to U.S. $ 23.9 billion in 2015. Overall, North America accounted for over 30% market share

With a CAGR of 7.9%, the global market for tissue banks market should be useful to U.S. $ 23.9 billion in 2015. Overall, North America accounted for over 30% market share. While the United States represent the largest share of the value of the global market on a national basis.

With a CAGR of 7.9%, the global market for tissue banks market should be useful to U.S. $ 23.9 billion in 2015. Overall, North America accounted for over 30% market share.

With a market value CAGR of 7.9% global market tissue banks are expected to be useful in the U.S. $ 23.9 billion in 2015. Worldwide, North America represents over 30% market share. While the U.S.

In 2009, China's government announced plans to invest RMB1.13 trillion ($180 billion) in expanding and improving healthcare provision, through significant healthcare reforms. This massive spending program is rapidly expanding healthcare access for China's 1.3 billion citizens, and has implications for the pharmaceutical industry worldwide. Inside China's Healthcare Reforms: Opportunities for Multinational Pharma This comprehensive report goes deep inside China to reveal the ways that recent reforms are changing healthcare for rural and urban citizens. Numerous local experts have been consulted for their insights, including industry experts, government officials, ministry advisers, and formulary managers. The reader-friendly report explores each key aspect of healthcare reform in turn, clearly explaining what it is, why it was needed, and what progress has been made so far, and then summarising its specific implications for the Pharma industry. As well as covering recent reforms, the report also examines key reform priorities through to 2015.

Estimates of current and projected products during the forecast period (2010-2015) are discussed. In addition, new products approved in 2009 and 2010 by the FDA and these products must be approved in the forecast period are projected